Researchers in Boston and across the world are racing to understand the true nature and utility of these promising cells, called induced pluripotent stem cells, or iPS cells. Read more…
KOOL expects revenues for Q4/10, to be approximately $7.3 M and to report a small net loss for the quarter, in the range of $150 K to $450 K, Read more…
GERN ended its joint venture with Hong Kong University of Science and Technology (HKUST) for undisclosed reasons. Read more…
BMTI was trading at $8.33 (3:30 pm) a share as of Friday (7/16/10) Read more…
The National Venture Capital Association (NVCA) has released Q/2 investment numbers, and once again the life sciences sector leads the pack. Read more…
ASTM initiated an extension study for control patients from the ongoing open-label Phase 2 IMPACT-DCM clinical trial in patients with dilated cardiomyopathy (DCM). Read more…
New data regarding the mechanisms of action of its lead CTX stem cell line in pre-clinical models of brain damage. The results of these studies showed that the CTX cells express several trophic and pro-angiogenic factors in culture and also induce endothelial cell markers Read more…
MSB’s positive results from its bone marrow transplant clinical trial conducted at the University of Texas MD Anderson Cancer Center resulted in a formal meeting being scheduled with the US FDA to discuss a proposed Phase 3 clinical trial program. Read more…
MCET.OB has retained Clinical Development & Support Services, Ltd. (CDSS) of Cheshire, England to manage its …planned … Phase IIb clinical trial in the UK for MCT-125; Read more…
Scientists have found a mutation in stem cell genes, which they claim could be linked to development of leukemia and other cancers. A major finding of a new study is the discovery of a novel DNA mutation in the c-Myb gene Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.